Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Fibrosis

• The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
• A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
• SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
• To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis
• A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
• ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial
• Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
• Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects
• Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
• Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia
• Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients
• A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis
• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
• Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites
• A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
• Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension
• Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
• A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients
• A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
• NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients
• Open-Label Dose-Escalation Treatment Study of Patients With IPF
• Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis
• Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
• High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment
• A Study to Investigate Leramistat in Patients With IPF
• Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
• A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
• Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
• A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).
• Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19
• Clinical Study of Allogeneic Adipovarian Active Protein in the Treatment of Severe Idiopathic Pulmonary Fibrosis
• Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age
• DOAC in Patients With Child B Liver Cirrhosis
• Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases
• A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
• Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
• 99mTc-HFAPI SPECT/CT in Pulmonary Fibrosis
• Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
• Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
• Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis
• A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
• Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
• A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
• A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
• The Anti-myocardial Fibrosis Effect of Vericiguat in HFrEF
• LiveSMART Trial to Prevent Falls in Patients With Cirrhosis
• Semaglutide in CFRD
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
• Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
• Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
• A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
• A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
• Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
• Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
• Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome
• Empagliflozin in Patients With Cirrhosis and Ascites
• Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis
• Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis
• Pilot Study to Assess Safety and Efficacy of an Enteric Microgranule Formulation of Adrulipase in Patients With Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis (CF).
• Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects
• Estrogen Patches for Adolescent and Young Adult Women With Cystic Fibrosis
• To Study the Hemodynamic Response of Early Addition of Carvedilol to Terlipressin in Acute Variceal Bleed in Child's B and C Cirrhosis
• Synbiotics Interventions for Managing Cirrhosis and Its Complications
• Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
• Opioid Sparing Anesthesia in Patients With Liver Cirrhosis Undergoing Liver Resection
• Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
• A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF)
• Coagulation in Cirrhosis
• Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis
• Treatment of Idiopathic Pulmonary Fibrosis(IPF) by REGEND001
• Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding
• Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
• Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes
• Study to Determine the Efficacy&Safety of ARV-1801/ACG-701 for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
• A Study in Participants With Non-cirrhotic NASH With Fibrosis
• Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
• Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
• Losartan in Prevention of Radiation-Induced Heart Failure
• A Study of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis
• Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) or Non-IPF Progressive Pulmonary Fibrosis
• Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
• Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
• Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
• Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
• Allopurinol to Prevent Cirrhosis Related Morbidities
• Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
• Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction
• Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
• Atezolizumab for Idiopathic Pulmonary Fibrosis
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF
• Allopurinol Versus Simvastatin to Prevent Complications of Liver Cirrhosis
• Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
• A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis
• To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
• Single Dose Escalation of PHIN-214 in Child-Pugh A Liver Cirrhotics
• To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
• Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
• Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
• Phase I Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
• Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
• A Phase 2 Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3
• A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
• 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid in Cirrhosis With Sepsis Induced Hypotension
• Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis
• A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
• Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
• Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis
• A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
• Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
• Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
• Safety and Effectiveness of EV-Pure + WJ-Pure Treatment on Pulmonary Fibrosis Secondary to Covid-19
• RESPIRARE Phase 2 Study of Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• FAPI PET for Lung Fibrosis
• A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis.
• A First-in-human Study of the Safety, Tolerability, and PK of XFB-19 in Healthy Adult Volunteers
• A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
• HRS-AKI Treatment With TIPS in Patients With Cirrhosis
• A Study to Evaluate the Safety and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
• LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
• Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency
• Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
• A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
• Different Doses of ZED1227 vs. Placebo in NAFLD
• Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
• To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.
• Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
• Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF
• Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
• Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
• Growth Hormone in Decompensated Liver Cirrhosis
• Xenon MRI and Progressive ILD
• Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis
• Probiotics and Hemodynamic Changes in Cirrhosis
• Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
• Effect of Imatinib in Advance Liver Fibrosis Patients
• Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
• To Study the Safety and Efficacy of Simvastatin in Patients With Hepatopulmonary Syndrome in Cirrhosis.
• Phase 2 Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With IPF
• Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
• Composition for Treating Cirrhosis and Liver Cancer (SB-1121)
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
• Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B
• The Effect and Safety of Tocilizumab Treatment on IRPF
• CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
• Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
• Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
• Efficiency of Pirfenidone for the Reduction of Pulmonary Metabolic, Inflammatory and Fibrogenic Activity in Patients With Silicosis Due to Artificial Stone and Progressive Massive Fibrosis
• Hydronidone for the Treatment of Liver Fibrosis Associated With Chronic Viral Hepatitis B Phase 3 Trial.
• A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
• Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis
• Phase II Study of a Nebulised Nitric Oxide Generating Solution in Patients With Cystic Fibrosis
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
• The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF
• Efficacy and Safety of Midodrine in Refractory or Recurrent Ascites in Children With Cirrhosis.
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Res
• Pirfenidone to Prevent Fibrosis in Ards.
• Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon
• A Trial to Improve Quality of Life in People With Cirrhosis
• To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)
• Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices
• Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
• Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).
• Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
• A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
• Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
• Empagliflozin in Diuretic Refractory Ascites
• Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
• Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
• Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
• Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) Admitted in ER
• Efficacy of Simvastatin in Alcoholic Liver Fibrosis
• A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Subjects With Cystic Fibrosis (CF)
• A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection
• Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
• Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
• Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
• Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
• A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
• Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.
• Sildenafil for Liver Fibrosis in Adolescents and Adults After Fontan Operation
• Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
• Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
• A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
• Danazol for Treatment of Cytopenias in Patients With Cirrhosis
• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis
• A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis
• Avatrombopaq In Patients With Cirrhosis
• 68Ga-FAPI PET/CT in Patients With Various Fibrotic Disease
• Colchicine and Post-COVID-19 Pulmonary Fibrosis
• Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.
• Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
• Clinical Study of Hepatocyte Transplantation for Liver Cirrhosis
• Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy
• A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis
• A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
• GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
• Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
• Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV With Hemophilia.
• Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
• CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
• Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.
• A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
• Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
• Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)
• HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.
• The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
• Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
• The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
• Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
• A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
• Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
• A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
• Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
• A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
• TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
• Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
• Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
• High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis
• A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
• Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis
• A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Subjects 6 Years and Older and F/MF Genotypes
• Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis
• Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis
• Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years
• 68Ga-FAPI PET/CT in Liver Fibrosis Patients
• Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes
• Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
• Effects of Metformin on Airway Ion Channel Dysfunction in Cystic Fibrosis-related Diabetes
• Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis
• Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
• Morphine for Dyspnea in Pulmonary Fibrosis
• Tranexamic Acid for Acute Upper Gastrointestinal Bleed in Cirrhosis
• Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
• Comparative Effect of Nigella Sativa and Conventional Management for OSMF
• Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
• Pharmacokinetics of Omadacycline in Cystic Fibrosis
• Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis
• Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial
• Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis
• Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
• Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
• Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis
• Anticoagulation Therapy After Splenectomy in Cirrhosis Patient
• Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
• Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis.
• Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes
• OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
• Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
• Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
• A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
• Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
• Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding
• A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes
• Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
• Roflumilast in Non-CF Bronchiectasis Study (2019)
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
• Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
• Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis
• Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
• A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
• Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs
• Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
• IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
• Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis
• Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
• Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu
• A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)
• Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis
• Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
• Hyperpolarized Imaging for New Treatments
• A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis
• HVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic Patients
• Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
• Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
• Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
• Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
• Prophylactic Antibiotics in Admitted Cirrhotics
• Losartan to Improve Hip Microfracture
• Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
• Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis
• Jin-shui Huan-xian Granule in the Treatment of IPF
• Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older
• Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients
• Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
• Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
• Erlotinib for Hepatocellular Carcinoma Chemoprevention
• Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis
• A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
• Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis
• A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
• A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
• Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis
• Granulocyte-Colony Stimulating Factor (G-CSF) as Optimizing Therapy for Pediatric Liver Transplantation
• A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
• A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
• Pirfenidone and Advanced Liver Fibrosis.
• A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver Cirrhosis
• Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
• Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis
• Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
• Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
• A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
• Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
• A Study of Oryz-Aspergillus Enzyme and Pancreatin Tablet in Patients With Cirrhosis and Malnutrition
• Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis
• Sorafenib PK in Patients With Advanced HCC and Child-Pugh B
• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
• Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
• Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)
• A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
• Sildenafil Exercise: Role of PDE5 Inhibition
• A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
• A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
• Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
• Healthy Volunteer Study Comparing Tablet and Capsule Formulations
• Efficacy and Safety of Testosterone Therapy in Improving Sarcopenia in Men With Cirrhosis.
• The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients
• A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
• Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients
• Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis
• Functional Respiratory Imaging and Orkambi in CF
• Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis
• A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis
• Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)
• Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
• Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
• A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
• A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocr
• Markers of Osteoporosis in Cystic Fibrosis
• Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis
• Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis
• A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
• A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
• GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT
• Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
• Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis
• Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.
• The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
• GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
• OCR002-SP103 - Oral Immediate Release Study
• A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
• A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis
• A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
• TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR)
• FMT in Cirrhosis and Hepatic Encephalopathy
• Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis
• Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2
• Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development
• Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis
• Effect of Some Drugs on Liver Fibrosis
• Description of the Evolution of Plasma and Urinary Concentrations of Iohexol in a Cirrhotic Patient Population
• Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
• N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial
• A DDI Study of FDL169 and FDL176 in Healthy Subjects
• Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF
• OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
• Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
• A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Pilot E2 for Hypogonadal Women With CFBD
• Inhaled NAC in Treatment of IPF
• Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
• A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
• SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
• Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis
• Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR
• An Evaluation of the Safety and Efficacy of NTZ on Collagen Turnover in NASH Patients With Fibrosis
• Effects of AD on VI in Patients With CF
• Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis
• A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
• Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
• Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C
• Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment
• Intravenous Iron in Adults With Cystic Fibrosis
• A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
• Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
• Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
• A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis
• Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.
• An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
• A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers
• Tadalafil for Erectile Dysfunction in Patients With Cirrhosis
• Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects
• First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis
• A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
• PPIs and Fat Absorption in CF and EPI
• Management of Decompensated HCV Cirrhotic Patients
• A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.
• JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR Mutation
• Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
• A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects
• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
• A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
• A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
• CF Bronchodilation
• Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
• A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects
• Efficacy of Curcumin in Oral Submucous Fibrosis
• Trikafta in Cystic Fibrosis Patients
• Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
• Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
• Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis
• 19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation
• Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine
• 19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
• DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis
• GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis
• A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
• Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS II)
• Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites
• Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
• Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis
• Safety, Tolerability and Pharmacodynamics of SYNB1020
• A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
• Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
• Roflumilast in Non-CF Bronchiectasis Study
• An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects
• This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.
• A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
• G-CSF in Decompensated Cirrhosis: an Open Label Trial
• Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
• Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis
• Propofol Versus Midazolam for Lower Gastrointestinal Endoscopy
• Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies
• Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
• Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
• In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis
• Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis
• A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
• Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
• Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
• Defined Green Tea Catechin Extract in Preventing Liver Cancer in Patients With Cirrhosis
• A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
• Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2)
• Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults
• Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy
• PTC Study to Evaluate Ataluren in Combination With Ivacaftor
• Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
• Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis
• Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunode
• An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
• A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
• A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
• Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection
• Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis
• Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
• Inhaled Nitric Oxide for Patients With MABSC
• Losartan and Inflammation in Cystic Fibrosis
• Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
• Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
• AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
• Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
• PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
• A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants
• Telavancin Pharmacokinetics in Cystic Fibrosis Patients
• To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis.
• SynRinse Irrigation Pilot (SIP) Trial
• Oral Fecal Transplant in Cirrhosis
• A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)
• Simvastatin Plus Rifaximin in Decompensated Cirrhosis
• Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis
• A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
• A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants
• Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
• Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis
• A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
• Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis
• Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue
• A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
• Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
• Clearance of 25-hydroxyvitamin D in Cystic Fibrosis
• Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection.
• A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
• Ramelteon for Treatment of Insomnia in Cirrhosis
• A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
• Prednisone in Cystic Fibrosis Pulmonary Exacerbations
• Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging
• Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis
• A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
• Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis
• Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation
• A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
• A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
• RESULT: Reliable, Emergent Solution Using Liprotamase Treatment
• A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis
• Effect of Azithromycin on Fatty Acids in CF
• Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV
• A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
• PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis
• Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding
• The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis
• Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea
• Anticoagulation for Advanced Cirrhotic Patients After TIPS
• A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
• Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
• Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest
• Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
• Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
• Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
• Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
• Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
• Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
• A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
• A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
• Saline Hypertonic in Preschoolers + CT
• A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis
• Multilevel Models of Therapeutic Response in the Lungs
• Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders
• An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
• Evaluation of Gastrointestinal Transit Pre and Pos Treatment With Non Selective Betablocker in a Population of Cirrhotics
• A Study of RPL554 in Patients With Cystic Fibrosis
• Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
• Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis
• FDGal PET/CT to Detect Hepatocellular Carcinoma
• Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer
• Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis
• Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients
• The Coagulation Cascade in Idiopathic Pulmonary Fibrosis
• A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
• Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
• A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
• Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
• Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
• The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia
• Evaluation of Hepatic Function Using Gadoxetic Acid Enhanced MRI
• Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients
• Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI
• Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
• LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients
• Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction
• Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease
• A Follow-up Evaluation Study of PRI-724-1101
• Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.
• EASY: Extended Access to Sollpura Over Years
• Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid
• Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
• Metabolic Effects of Furosemide +HSS in Refractory Ascites
• ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor
• A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment
• Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years
• Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients
• Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
• Standardized Treatment of Pulmonary Exacerbations II
• Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
• Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
• Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
• Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis
• CleanUP IPF for the Pulmonary Trials Cooperative
• Comparison of Standard Dose Versus Once a Day Intravenous Albumin in Spontaneous Bacterial Peritonitis
• Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
• A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
• Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease
• Efficacy and Safety of Endoscopic Variceal Ligation (EVL) Versus EVL Plus Non-selective B-blockers (NSBB) For Prevention of Variceal Rebleed and Non-bleed Related Complications in Patients With Advanced Cirrhosis
• Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
• Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
• Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
• SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
• Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis
• Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
• A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
• Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor
• Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®
• A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients
• Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis
• Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study
• Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
• A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
• A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)
• Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
• Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
• Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)
• Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)
• A Phase 2 Study of the Activity and Safety of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
• Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
• Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
• Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)
• Serelaxin To Lower Portal Pressure
• Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis
• Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del
• Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
• A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
• Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF)
• Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis
• Cyclobenzaprine in Muscle Cramps With Liver Cirrhosis
• Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
• To Assess the Efficacy of Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy in Patients of Decompensated Cirrhosis
• The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices
• Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
• Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)
• First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
• Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
• All-Case Surveillance of Ofev in Patients With IPF in Japan
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
• Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis
• Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
• Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients
• Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
• Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
• Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease
• Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
• Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
• Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation
• Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
• Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
• Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor
• A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
• The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis
• To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
• Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis
• Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
• ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
• A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients
• A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
• A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
• 68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
• Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis
• Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices
• Surrogate Markers of Portal Pressure
• A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
• Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis
• Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
• Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
• The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients
• Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis
• 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis
• Evaluation of Intestinal Permeability in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol)
• Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis
• A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
• Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
• Metformin Experience on Minimal Hepatic Encephalopathy
• To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock
• To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.
• Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
• Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
• To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis
• Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
• Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension
• Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
• Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis
• A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection
• Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study
• Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
• Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)
• Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
• EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
• Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial
• Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial
• Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis
• Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
• Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
• Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
• Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection
• A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Respons
• Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFT
• Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
• The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding
• Saline Hypertonic in Preschoolers
• Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
• IBAT Inhibitor A4250 for Cholestatic Pruritus
• A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
• Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
• Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis
• Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis
• Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
• Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)
• Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis
• Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients
• Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis
• Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
• Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)
• An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
• Primary Prevention Hepatocellular Carcinoma by Metformin
• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
• Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study
• Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis
• RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study
• A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
• A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
• A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
• SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis
• A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index
• Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
• Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV)
• Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
• Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients
• Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients
• 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
• Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients
• To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism
• A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
• RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
• Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation
• Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa
• Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
• Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV
• Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
• DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis
• A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
• Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy
• Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance
• Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
• A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
• A Study of IDN-6556 in Subjects With Liver Cirrhosis
• PK Study of N91115 in Cystic Fibrosis Patients
• Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)
• Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C
• Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
• Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infectio
• Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex
• First Study of Oral Cysteamine in Cystic Fibrosis
• Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
• Redox Imbalance and the Development of Cystic Fibrosis Diabetes
• Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
• An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis
• Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation
• Pilot Study of FFP104 Dose Escalation in PBC Subjects
• Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
• Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial
• Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
• Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites
• Azithromycin in Idiopathic Pulmonary Fibrosis
• Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients
• Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)
• Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
• A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
• Pirfenidone, an Antifibrotic and Antiinflammatory Drug
• A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis
• LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
• Cystic Fibrosis Related Diabetes
• Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study
• Contraceptive Hormones and Women With Cystic Fibrosis
• Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis
• A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device
• Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
• Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
• A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
• A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
• Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
• Simvastatin Effect on Portal Hypertension
• A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
• Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
• Study of Ataluren (PTC124) in Cystic Fibrosis
• Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)
• Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.
• Novartis Everolimus Transition
• Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis
• Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)
• Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
• Rifaximin Predicts the Complications of Decompensated Cirrhosis
• Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
• Mesenchymal Stromal Cell Therapy in Renal Recipients
• Blood Flow and Vascular Function in Cystic Fibrosis
• Nandrolone Decanoate in the Treatment of Telomeropathies
• OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
• Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
• Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
• Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis
• Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
• Gender Disparity and Hormones in Cystic Fibrosis
• Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study
• Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy
• Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
• Molecular MRI of the Fibrotic Heart
• Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis
• A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
• A Study to Investigate Lung Deposition of Radiolabelled OligoG
• Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
• Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars
• Investigating the Incretin Effect in Cystic Fibrosis
• Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis
• A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
• Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function
• Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis
• Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
• A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis
• Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis
• Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
• Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients
• Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
• A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Viru
• Optimized Treatment and Regression of HBV-induced Early Cirrhosis
• Optimized Treatment and Regression of HBV-induced Liver Fibrosis
• CPET in CF Patients With One G551D Mutation Taking VX770
• Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
• Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV
• Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
• A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
• Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)
• Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab
• Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
• Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis
• Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
• Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
• A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
• Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
• Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients
• Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
• Repeatability and Response Study of Absorptive Clearance Scans
• Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years
• Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
• Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis
• Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
• A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
• An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
• Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis
• Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
• Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
• Beta-cell Response to Incretin Hormones in Cystic Fibrosis
• Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
• Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate
• Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
• The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
• Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
• Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit
• Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen
• Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
• Treatment of Low Bone Density in Cystic Fibrosis.
• Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
• Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects
• Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial
• A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
• Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients
• Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
• Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
• Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis
• Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
• Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
• Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
• Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)
• Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis
• Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
• Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
• A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• L-ornithine L-aspartate in Overt Hepatic Encephalopathy
• Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis
• Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis
• Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients
• A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis
• Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
• Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen
• The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
• Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
• Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation
• A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compens
• Zoledronic Acid in Cystic Fibrosis
• VSL#3 and Spontaneous Bacterial Peritonitis
• Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
• Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
• Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis
• Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
• Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
• Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis
• A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
• Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
• Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
• An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
• An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
• Repeated Application of Gene Therapy in CF Patients
• Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
• Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis
• Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis
• Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant
• Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
• Probiotics for Liver Cirrhosis With Portal Hypertension
• Rituximab in IgG4-RD: A Phase 1-2 Trial
• ATCF (Azole Therapy in Cystic Fibrosis)
• Effect of Tolvaptan on Cognitive Function in Cirrhosis
• A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
• Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation
• Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis
• ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study
• Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
• To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
• Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
• Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis
• Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)
• Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
• Keyhole Limpet Hemocyanin in Chronic Hepatitis C
• Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis
• Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
• Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis
• Treatment of Muscle Cramps in Patients With Liver Cirrhosis
• Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
• Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
• A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis
• Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation
• Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
• Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis
• Proton Pump Inhibitors and Dysbiosis in Cirrhosis
• IPF Drug Deposition Study
• Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension
• Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients
• Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
• Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis
• Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
• The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS
• Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
• Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding
• Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody
• Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
• Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
• Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways
• Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis
• A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
• Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)
• Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis
• Aztreonam Lysine for Pseudomonas Infection Eradication Study
• STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis
• Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
• Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
• Nephrogenic Systemic Fibrosis With Gadollinum
• Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis
• Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
• Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites
• Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
• Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis
• Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection
• Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
• Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis
• Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
• Doxycycline Effects on Inflammation in Cystic Fibrosis
• Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
• Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
• Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone
• Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo
• Hypertonic Saline and Mucociliary Clearance in Children
• Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis
• Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis
• Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
• Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
• Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis
• Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
• A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis
• Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
• Prevention of Bronchiectasis in Infants With Cystic Fibrosis
• Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis
• Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
• Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC
• Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
• Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
• Sitagliptin in Cystic Fibrosis-Related Diabetes
• Pentoxifylline for Primary Biliary Cirrhosis
• Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial
• Mesenchymal Stem Cells Treat Liver Cirrhosis
• Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
• Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
• Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients
• Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
• Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients
• Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis
• Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
• Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis
• A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
• Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
• Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
• ¹³C-Methacetin Breath Test (MBT) Methodology Study
• A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
• Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
• Early Primary Prophylaxis of Esophageal Varices
• Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.
• Sildenafil Trial in Children and Young Adults With CF
• Intravenous Interferon During Liver Transplant
• Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis
• A Safety and Tolerability Study of Denufosol in 2-4 Year Olds
• MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis
• Tiotropium Bromide in Cystic Fibrosis
• Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
• Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
• Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients
• Pulmozyme in Cystic Fibrosis With Sinusitis
• Cystic Fibrosis (CF) Exacerbation and Insulin Treatment
• Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial
• Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis
• Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients
• Extension Study of Ataluren (PTC124) in Cystic Fibrosis
• Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
• Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
• Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR
• Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis
• Probiotics for Portal Hypertension
• Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment
• Effects of Sildenafil on CFTR-dependent Ion Transport Activity
• PR-018: An Open-Label, Safety Extension of Study PR-011
• Rollover Study of VX-770 in Cystic Fibrosis Subjects
• Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer
• A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
• Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients
• A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
• Cystic Fibrosis - Insulin Deficiency, Early Action
• A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
• Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy
• Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding
• Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis
• A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients
• Statins To Treat Adult Cystic Fibrosis
• Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa
• Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
• Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
• Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
• Spironolactone in Adult Congenital Heart Disease
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection
• Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
• A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema
• A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg
• Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
• Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure
• Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
• Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis
• A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
• Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
• Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?
• A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
• A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
• Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein
• Effect of Candesartan in Alcoholic Liver Fibrosis
• Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
• Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin
• Open Label Extension to Bridging Study CTBM100C2303
• Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec
• Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
• Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
• Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
• Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
• Prevention of Cystic Fibrosis Diabetes
• Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
• Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding
• AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
• Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
• A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
• Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?
• Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)
• Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
• Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects
• A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis
• A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo
• Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
• Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
• Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients
• Primary Prophylaxis of Gastric Varix Bleed
• Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
• 28 Day Repeat Dose in Cystic Fibrosis Patients
• Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis
• Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients
• Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"
• Secondary Prophylaxis Gastric Variceal Bleed
• Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis
• A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
• Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)
• Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer
• Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
• Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
• Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
• Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis
• Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
• Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers
• Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis
• Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)
• Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis
• RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
• "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"
• Safety of Gadovist in Renally Impaired Patients
• Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction
• Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis
• Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)
• NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients
• Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis
• Study of Ataluren (PTC124™) in Cystic Fibrosis
• Growth Hormone Therapy for Wasting in Cystic Fibrosis
• Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
• Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection
• Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
• Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients
• Single Dose of pGM169/GL67A in CF Patients
• An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
• A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
• Phase II Study of Digitoxin to Treat Cystic Fibrosis
• Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study
• Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
• Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
• Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
• Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)
• (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
• Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
• Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
• Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients
• A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
• Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
• Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis
• Rifaximin Versus Lactulose in Renal Failure
• Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)
• Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
• Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
• Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency
• Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome
• Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
• Miglustat in Cystic Fibrosis
• Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)
• Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
• Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis
• Effect of Pioglitazone on Inflammation in Cystic Fibrosis
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
• Infant Study of Inhaled Saline in Cystic Fibrosis
• Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes
• Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis
• Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
• Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
• Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways
• Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
• Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)
• Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay
• Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)
• Choline Nutrition in Children With Cystic Fibrosis (CF)
• A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis
• Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial
• Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
• Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
• Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis
• Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients
• Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
• Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis
• A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
• Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
• Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function
• Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
• Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
• Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
• Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
• Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study
• The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis
• Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
• Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
• Long Term Administration of Inhaled Mannitol in Cystic Fibrosis
• Terlipressin in Septic Shock in Cirrhosis
• Self-dispersing Liquids as Aerosol Drug Carriers
• Pharmacokinetics of Linezolid in Children With Cystic Fibrosis
• Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease
• Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
• Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
• Repeat Dose Study in Male Healthy Volunteer Smokers
• Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
• SD Cystic Fibrosis Study
• Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
• Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension
• A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
• Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)
• Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
• Moexipril for Primary Biliary Cirrhosis
• Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis
• Trental & Vitamin E for Radiation-Induced Fibrosis
• Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
• QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
• Use of Fenofibrate for Primary Biliary Cirrhosis
• Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis
• Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)
• Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis
• Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis
• IGF-1 Therapy in Patients With Cystic Fibrosis
• A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
• A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis
• Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
• The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
• Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
• Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis
• Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis
• Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis
• TCM Etiological Study on the Theory of XuSunShengJi in Liver Cirrhosis
• Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation
• Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
• The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
• Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
• SD, IL-13 Production Rate in IPF
• Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
• Efficacy of Baclofen in the Treatment of Alcohol Addiction
• Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis
• Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
• Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo
• Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
• Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
• Lyspro Insulin vs Regular Insulin in Cirrhotic Patients
• Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
• Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis
• Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients
• Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis
• Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients
• Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
• Fibrosis in Renal Allografts
• Study of Combivir for Patients With Primary Biliary Cirrhosis
• Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
• One Year Glargine Treatment in CFRD Children and Adolescents
• A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
• Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients
• Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
• Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide
• Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis
• A Study of Ataluren in Pediatric Participants With Cystic Fibrosis
• Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
• Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
• A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis
• Improving Vitamin D Status In Cystic Fibrosis
• Open-Label Phase III Long-Term Safety Trial of Liprotamase
• Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
• Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study
• Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
• Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
• A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
• Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
• Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa
• Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction
• Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease
• Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study
• Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
• Scandinavian Cystic Fibrosis Azithromycin Study
• Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.
• Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)
• Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis
• The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
• CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
• Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study
• Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
• BUILD 3: Bosentan Use in Interstitial Lung Disease
• Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis
• Lumbar Spinal Fibrosis and TNF Alpha Inhibition
• Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients
• Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
• Initial Study of Rituximab to Treat Primary Biliary Cirrhosis
• Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
• Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
• Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
• Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)
• Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease
• The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients
• Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
• PTC124 for the Treatment of Cystic Fibrosis
• Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
• Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis
• Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
• Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis
• A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
• Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
• Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease
• Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
• Probiotics for the Prevention of Major Complications of Cirrhosis
• Hydroxychloroquine in Cystic Fibrosis
• Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
• Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.
• A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
• Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
• Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex
• Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
• Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
• Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
• Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
• Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin
• Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.
• Growth Hormone Use in Adolescents and Adults With Cystic Fibrosis
• Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
• The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
• A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
• Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis
• Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
• Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
• The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis
• Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
• Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis
• Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
• Growth Hormone Treatment Study in Children With Cystic Fibrosis
• Effect of Simvastatin on CF Airway Inflammation
• Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
• Mannitol Dose Response Study in Cystic Fibrosis
• DOCICAR: Cardiac Dysfunction in Cirrhosis
• Development of a Breath Test for Monitoring Patients With Liver Disease
• Prevention of Decompensation in Liver Cirrhosis
• Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis
• PTC124 for Cystic Fibrosis
• Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
• Insulin Glargine Vs Standard Insulin Therapy
• Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis
• Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)
• Assessment of Inflammatory Mediators (AIM)
• Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis
• An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption
• Selenium Supplementation of Patients With Cirrhosis
• Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis
• Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study
• Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
• Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
• Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients
• Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
• Effectiveness of Pulmozyme in Infants With Cystic Fibrosis
• Study of Long-term Peg Intron vs. Colchicine in Non-responders.
• The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation
• Urotensin II and Vascular Tone in Cirrhosis
• Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis
• Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
• Clinical Trial of Pentoxifylline in Patient With Cirrhosis
• Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
• Use of NovoSeven® in Active Variceal Bleeding
• Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)
• Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
• Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
• Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
• A Study in Pediatric Patients With Cystic Fibrosis Lung Disease
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
• Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
• SAMe to Treat Biliary Cirrhosis Symptoms
• Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis
• Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C
• Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis
• Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites
• International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
• Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
• Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
• Zinc Homeostasis and Kinetics in Children With Cystic Fibrosis (CF)
• Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
• Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
• Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
• Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)
• Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
• A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis
• Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer
• Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy
• An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
• Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
• The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
• Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
• Diabetes Therapy to Improve BMI and Lung Function in CF
• Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
• Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
• Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis
• Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients
• Treatment of Cholestatic Pruritus With Sertraline
• Gabapentin to Treat Itch in Patients With Liver Disease
• Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
• An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone
• A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
• Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis
• Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
• Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
• A Study in Adult and Pediatric Patients With Cystic Fibrosis
• Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer
• Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)
• Phase II Study of Growth Hormone in Children With Cystic Fibrosis
• Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis
• Prevention of Esophageal Varices by Beta-Adrenergic Blockers
• A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis
• Ursodiol-Methotrexate for Primary Biliary Cirrhosis
• Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
• Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis
• Growth Hormone Use in Cystic Fibrosis - a Multicenter Study
• A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis
• Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia
• Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
• Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis
• Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis
• Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
• Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis
• Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis
• Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis
• Prevention of Esophageal Varices by Beta-Adrenergic Blockers
• Scleroderma Lung Disease
• Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis
• Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis
• Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
• Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis
• Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis
• Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis
• Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease
• Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
• Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
• Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis